Autoimmune diseases (AIDs) refer to connective tissue inflammation caused by aberrant autoantibodies resulting from dysfunctional immune surveillance. Most of the current treatments for AIDs use non-selective immunosuppressive agents. Although these therapies successfully control the disease process, patients experience significant side effects, particularly an increased risk of infection. There is a great need to study the pathogenesis of AIDs to facilitate the development of selective inhibitors for inflammatory signaling to overcome the limitations of traditional therapies. Immune cells alter their predominant metabolic profile from mitochondrial respiration to glycolysis in AIDs. This metabolic reprogramming, known to occur in adaptive immune cells, i.e., B and T lymphocytes, is critical to the pathogenesis of connective tissue inflammation. At the cellular level, this metabolic switch involves multiple signaling molecules, including serine–threonine protein kinase, mammalian target of rapamycin, and phosphoinositide 3-kinase. Although glycolysis is less efficient than mitochondrial respiration in terms of ATP production, immune cells can promote disease progression by enhancing glycolysis to satisfy cellular functions. Recent studies have shown that active glycolytic metabolism may also account for the cellular physiology of innate immune cells in AIDs. However, the mechanism by which glycolysis affects innate immunity and participates in the pathogenesis of AIDs remains to be elucidated. Therefore, we reviewed the molecular mechanisms, including key enzymes, signaling pathways, and inflammatory factors, that could explain the relationship between glycolysis and the pro-inflammatory phenotype of innate immune cells such as neutrophils, macrophages, and dendritic cells. Additionally, we summarize the impact of glycolysis on the pathophysiological processes of AIDs, including systemic lupus erythematosus, rheumatoid arthritis, vasculitis, and ankylosing spondylitis, and discuss potential therapeutic targets. The discovery that immune cell metabolism characterized by glycolysis may regulate inflammation broadens the avenues for treating AIDs by modulating immune cell metabolism.

Keywords: autoimmune diseases, innate immune cells, immunometabolism, glycolysis, therapeutic target
INTRODUCTION

Autoimmune diseases (AIDs) encompass various chronic disorders involving multiple organs and have various clinical manifestations caused by connective tissue inflammation (1). Most of the current treatments for AIDs use non-selective immunosuppressive agents. Although these therapies successfully control the disease process, patients inevitably suffer from various side effects, particularly an increased risk of infection (2). Investigating the pathogenesis of AIDs is crucial for developing novel selective immunotherapies.

Immune tolerance is established during the maturation of immune cells in the bone marrow and peripheral lymphoid organs (3). Aberrant antigen presentation and differentiation of B cells into autoantibody-secreting plasma cells lead to the development of AIDs (3). Multiple signals that activate the differentiation of CD4+ T lymphocytes are destroyed in AIDs, leading to the breakdown of immune tolerance (4, 5). Hyperactive immune responses triggered by pathogenic autoantibodies are responsible for uncontrolled inflammation in connective tissue (6). Increasing lymphocytes accumulate in lesion locations and even form ectopic germinal centers as the disease progresses (6). However, abnormalities in cell development and function are not limited to T and B cells (7). Recently, it has been suggested that metabolic abnormalities in innate immune cells play a critical role in the pathogenesis of AIDs, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (8, 9). However, the comprehensive mechanism of innate immunity involvement in AIDs remains to be elaborated.

Glucose metabolism is an important metabolic pathway that provides energy to cells and consists of multiple enzymes that catalyze the conversion of glucose into metabolized products and energy in the form of ATP (10). As shown in Figure 1, glucose transported into the cytoplasm undergoes glycolysis, and the produced pyruvate is used mainly in oxidative phosphorylation (OXPHOS) after the tricarboxylic acid (TCA) cycle to generate more ATP. Glycolytic intermediates glucose-6-phosphate (G6P) and 3-phosphoglycerate are involved in the pentose phosphate pathway (PPP) and amino acid synthesis, respectively. In addition to providing energy, glycolytic intermediates support immune cells in reprogramming their phenotypes in response to external stimuli (11, 12). Thus, although glycolysis is less efficient than the TCA cycle or OXPHOS in producing ATP, it serves as an important metabolic pathway for activated immune cells (13). During active inflammation, immune cells use glycolysis as the major metabolic pathway to meet the demands of inflammatory activity whereas, they restore OXPHOS during the resolution of inflammation (14). Recently, it has become evident that the glycolytic switch in AIDs determines the fate of immune cells and affects the inflammatory response. More importantly, increasing metabolism has been well characterized in innate immune cells involved in AIDs (15, 16). However, the mechanism by which glycolytic activity in innate immune cells is involved in the pathogenesis of AIDs remains unclear.

In this review, we discuss the mechanisms through which glycolysis alters innate immune cells and how metabolic pathways control inflammatory responses in AIDs, thus providing insights for developing new therapeutic targets.

ROLE OF GLYCOLYSIS IN INNER IMMUNE CELLS

The Warburg effect is important for understanding metabolic changes that occur in innate immune cells upon activation (Figure 2). In resting immune cells, pyruvate can enter the TCA cycle for complete oxidation to CO₂, generating reduced nicotinamide adenine dinucleotide and reduced flavin adenine dinucleotide. This process produces energy efficiently. In contrast, in an inflammatory microenvironment, pyruvate in immune cells undergoes aerobic glycolysis and regenerates nicotinamide adenine dinucleotide to rapidly meet the demands of a pro-inflammatory phenotype (17). The upregulation of glycolytic activity is caused by multiple processes, including the transfer of extracellular glucose into the cell (glucose transporter, GLUT), the breakdown of glucose (hexokinase, HK), and the conversion of glucose-6P to pyruvate (gliceraldehyde-3-phosphate dehydrogenase, GAPDH; pyruvate kinase isoenzyme M2, PKM2) (Figure 1) (18, 19). Besides, G6P undergoes oxidative decomposition in the PPP to generate nicotinamide adenine dinucleotide phosphate (NADPH) and ribose 5-phosphate. This metabolic branch provides the essential metabolite ribose 5-phosphate for nucleotide biosynthesis and cell proliferation (20). The abundantly produced NADPH in PPP supplies reducing power for synthetic reactions, providing antioxidant defenses for cells (20). Thus, those highly NADPH-dependent hydroxylases are manipulated by PPP activity, such as kynurenine 3-hydroxylase (21) (Figure 1). Immune receptors on the cell surface induce a phenotypic switch in immunometabolism. Immune receptors activate various transcription factors to induce the expression of glycolytic genes via kinase signaling pathways, including phosphatidylinositol 3 kinase (PI3K)/serine-threonine protein kinase (Akt), mammalian target of rapamycin (mTOR), and mitogen-activated protein kinase (MAPK) (22, 23). Hypoxia-inducible factor 1α (HIF-1α) nuclear factor kappa B (NF-kB) are major transcription factors mediating immunometabolic and inflammatory activities, inducing glucose uptake, glycolysis, and lipid synthesis (24, 25). mTOR can form different protein complexes, mTOR complexes 1 and 2 (mTORC1 and mTORC2). mTORC2 is responsible for controlling Akt activation through phosphorylation, while PI3K/Akt activates mTORC1 (17). mTORC2 enhances GLUT1 expression and aerobic glycolytic activity. mTORC1 is not only involved in the signaling of glycolysis but also promotes the synthesis of proteins and lipids (17). mTOR signaling is an important regulator of intracellular metabolic activity.

Neutrophils

Glycolysis is the main energy production pathway for neutrophils, although glucose is also metabolized via the hexose monophosphate pathway. Mitochondria in neutrophils are not the main source of ATP. The mitochondria in neutrophils are primarily involved in the
initiation of cell death. Therefore, the energy required for inflammatory functions and phagocytic activity originates from glycolysis in these cells (26). Phagocytosis by neutrophils involves the uptake of pathogens into plasma membrane-derived vacuoles and subsequent fusion of lysosomes with pathogen-containing phagosomes. Sodium iodoacetate, which selectively inhibits glycolysis by irreversibly inhibiting GAPDH, and 2-deoxyglucose (2-DG), which inhibits both glycolysis and PPP by competitively inhibiting G6P production, is reported to inhibit neutrophil phagocytosis (27, 28).

Neutrophils that migrate to inflammatory tissues can kill pathogens through phagocytosis, proteolytic enzymes, and reactive oxygen species (29). Neutrophils also function by releasing antimicrobial granules extracellularly (29). Antimicrobial...
peptides and chromatin released by neutrophils form an extracellular network that binds pathogenic microorganisms and limits the progress of infection. These extracellular fiber-structures are called neutrophil extracellular traps (NETs) (29). Scientists believe that neither NETs nor the chromatin within them originate from cell disintegration. However, mature neutrophils die within a short time after entering the circulation. The formation of NETs is likely an early event in neutrophil death (29). Various microorganisms, bacterial products, and pharmacological stimuli, such as 2-acetoxy-1-methoxypropane, induce NETs formation (30). Stimulation with 2-acetoxy-1-methoxypropane results in increased GLUT levels, glucose uptake, and glycolysis rates. However, when neutrophils are exposed to 2-acetoxy-1-methoxypropane under low glucose conditions, polymorphic nuclei are not maintained, and NETs are not formed (30). This suggests that NETs formation is strictly dependent on glucose levels. G6P, a glycolytic intermediate, enters the PPP. Nicotinamide adenine dinucleotide phosphate (NADPH) is produced during the oxidative phase of the PPP, which maintains NADPH oxidase 2 activity and reactive oxygen species (ROS) production. Both G6P and NADPH are involved in chromatin depolymerization, NADPH oxidase 2-dependent NET formation and NET release (31). NADPH appears to be the core metabolite supporting NETs. The glycolysis inhibitor 2-deoxyglucose (2-DG) affects NET formation (30). Mechanistically, after HK2 is blocked by 2-DG, G6P as the substrate for HK2 decreases immediately. Additionally, the metabolism of glucose to pyruvate in the cytoplasm generates relatively low levels of ATP and NADPH. Neutrophils use aerobic glycolysis to reduce pyruvate to lactate (which is processed by lactic dehydrogenase A, LDHA) and recycle the resultant NAD⁺ in glycolysis. Therefore, impairing LDHA also restrains the induction of NETs (32). The glucose-6-phosphate transporter/G6Pase-β complex regulates energy metabolism, glycolysis, and the PPP, in neutrophils by controlling G6P levels in the cytoplasm (31). Disturbances in glucose metabolism caused by defective glucose-6-phosphate transporter activity impair neutrophil function, including chemotaxis and ROS production (33). Moreover, NETs formation is, to some extent, dependent on glutamine and, to a lesser extent, affected by the ATP synthase inhibitor oligomycin (30).

Optic atrophy 1 (OPA1) is a mitochondrial structural protein that is essential for mitochondrial integrity and plasticity. Meanwhile, OPA1-dependent ATP is required for the formation and maintenance of NETs (34). Mechanistically, OPA1 in neutrophils can ensure the generation of NAD⁺ by maintaining the activity of electron transport complex I. Dysfunctional OPA1 reduces the NAD⁺ levels, which results in a consequent decrease in ATP from glycolysis. This suggests that glycolytic ATP plays an important role in the formation of NETs (34). Additionally, dimethyl malonate acts as a neutrophil succinate dehydrogenase inhibitor and reduces NETs release (35). These results suggest that glycolysis may be involved in NET formation through various biological mechanisms.

Macrophages

The plasticity of macrophages enables them to switch from one phenotype to another in response to stimuli from the microenvironment (36, 37). The balance between different macrophage subtypes maintains health, while phenotype dysregulation of macrophages contributes to the development of diseases, including AIDs (38). Although the M1/M2 classification has been found insufficient to represent the diversity and complexity of macrophage subtypes as two distinct phenotypes with distinct functions, M1/M2 typing can reflect the plasticity of phenotypic transition. Interferon gamma (IFN-γ) secreted by helper T cells and bacterial lipopolysaccharide can induce macrophage differentiation to classically activated M1 (inflammatory). They produce inflammatory cytokines that are involved in pathogen elimination activities and interfere with wound healing and tissue repair (39, 40). These cytokines underlie the pathology of M1 macrophage-mediated AIDs (41). Indoleamine (2,3)-dioxygenase (IDO) is highly expressed in M1 macrophages and orchestrates tryptophan-kynurenine metabolism (42). Kynurenine stimulation alters the phenotype of human T cells via the eukaryotic translation initiation factor 4E binding protein 1/mTORC1 axis (43). Microenvironment-derivered interleukin (IL)-21, IL-33, IL-10, and Th2-cell-derived IL-13 and IL-4 all boost macrophage polarization to the M2 type (39). This polarization appears to be a negative feedback regulation of inflammatory responses in the microenvironment, as M2-like macrophages facilitate inflammation resolution and wound healing (38) via secretion of the vascular endothelial growth factor and transforming growth factor-beta.

Alterations in metabolic signature support functional switching. Macrophages use OXPHOS in the resting state. M1 macrophages overexpress GLUT1 and catabolize arginine to produce nitric oxide and ROS (44). PKM2 in these cells is mobilized and phosphorylated (45), contributing to IL-1β transription via signal transducer and activator of transcription (STAT) 3 signaling (46). M1 macrophages are heavily dependent on glycolysis and undergo two disruptions in the TCA cycle, resulting in an accumulation of citrate acid, succinic acid, and lactate (47). Mechanistically, 1) Downregulated isocitrate dehydrogenase caused by metabolic reprogramming inefficiently converts isocitrate to α-ketoglutarate; and 2) A large amount of itaconic acid in M1 macrophages not only limits the function of succinate dehydrogenase, resulting in substrate accumulation, but also enhances the activity of lactate dehydrogenase. As a signaling hub for toll-like receptors (TLRs), solute carrier family 15 member A4 is likely to maintain the interaction of adenosine monophosphate-activated protein kinase (AMPK) and mTORC1 by acting as a scaffold (48). Activation of TLR/AMPK/mTORC1 signaling is critical for the induction of M1-like metabolic phenotype and IL-12 secretion (48).

In contrast, M2 macrophages, which have an intact TCA cycle that provides substrates for the electron transport chain, are involved in tissue repair and wound healing and use oxidative metabolism to fuel their long-term functions (47). The inflammasome activity in M1 macrophages is regulated by NETs and ATP-binding cassette transporter A1/G1/cholesterol crystal dual signaling in tissues (49–51), followed by upregulation of...
several glycolytic signals such as Eno3, Aldoc, Bpgm, Pgam1, Pgam2, Pkm, and Hk3 (52). Conversely, M2 macrophages exhibit a similar level of glycolysis as unstimulated cells (53, 54). This may result from the upregulated gene expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB) 1 induced by M2-type activating signals. Phospho-fructokinase 2 encoded by PFKFB1 exhibits lower activity than that encoded by PFKFB3, thereby reducing glycolytic flux (53). Inhibiting glycolysis does not affect IL-4-induced macrophage activation without blocking OXPHOS. When OXPHOS and glycolysis were simultaneously inhibited (high doses of 2-DG, 10 mM), M2 differentiation was hindered (55). Based on the results of several recent studies, investigators suggest that glycolysis is also involved in M2 activation. Low doses of 2-DG (1 mM) can downregulate the expression of a series of M2-like gene profiles, including Arg1, Cd1m, Ym1, Mrc1, and resistin-like β through the Akt/mTORC1 signaling pathway (56–58). The IFN regulatory factor 4, which is downstream of the IL-4 receptor α/STAT6 and colony-stimulating factor 1 receptor/mTORC2 signaling axis, promotes glycolysis (enhanced expression of LDHA, GAPDH and HK2) and M2 activation (59). These results suggest that M2 activation is preferentially dependent on OXPHOS, but glycolysis is required if OXPHOS is impaired. Additional studies must elucidate the role of glycolysis in M2 activation.

Recruited by apoptotic cells, the process by which macrophages recognize, engulf, and degrade dying cells is called efferocytosis (60). Macrophages in the injured tissue exhibit exocytosis, and their metabolite load becomes equivalent to that of phagocytes (61). However, the rise in IL-10 levels observed during efferocytosis is regulated by mitochondrial β-oxidation and the electron transport chain and is not dependent on glycolysis (62). Conversely, the chemotactic behavior of macrophages in the inflammatory microenvironment relies on glycolysis, both in vivo and in vitro (63). ATP generated by glycolysis can rapidly replenish the energy required for actin synthesis and pseudopodia extension under mild hypoxia in the inflamed area (63).

Activation of myeloid-derived cells by microbial β-glucan is mediated through metabolic pathways that induce epigenetic reprogramming, also known as “trained immunity” (64). Metabolic and transcriptomic data suggest that glutaminolysis and glycolysis are involved in β-glucan-induced immune reprogramming of monocytes. Glutamine-induced accumulation of fumarate in the TCA cycle can inhibit histone demethylase lysine-specific demethylase 5A to initiate epigenetic reprogramming in monocytes (65). This is consistent with metabolic changes in glucose mass consumption, lactate production, and inversion of the NAD+/NADH ratio observed in trained monocytes (52).

The Akt/mTOR/HIF-1α signaling axis regulates glycolysis in monocytes (66). Metformin activates AMPK and inhibits the antibacterial activity of monocytes that is induced by mTOR. This is also observed in the mTOR inhibitor rapamycin. Solute carrier family 15 member A4 is an amino acid/oligopeptide transporter in immune cells (67). Additionally, stimulation of the extracellular immune complex (IC) can activate HIF-1α signaling via the Syk/Erk/mTOR and Syk/PI3K/Akt/mTOR pathways, resulting in a switch of macrophage energy metabolism to glycolysis. Fcγ receptor IIb and αFcγ receptor are involved in the transduction of extracellular IC signals (68). This metabolic switch is observed in renal Fcγ receptor IIb-depleted macrophages associated with decreased glycolytic activity, increased mitochondrial respiratory activity, and respiratory reserves in antibody-mediated nephritis (69). Overall, these findings suggest that inhibition of glycolysis in macrophages reduces tissue inflammation, highlighting its potential as a therapeutic strategy for AIDs.

**Dendritic Cells (DCs)**

As the primary antigen-presenting cells of the peripheral immune system, DCs act as a bridge between innate and adaptive immunity and are also responsible for inducing lymphocyte activation and differentiation (70). Non-activated DCs exhibit oxidative metabolism. Pathogen-associated molecular patterns bind TLRs on DCs and induce chemokines and inflammatory factors. TLRs signaling, upregulation of glycolytic activity, and increased lactate production are within the scope of Warburg physiology (71). Additionally, mitochondrial activity is progressively lost following TLR signaling. Moreover, both glucose deprivation and 2-DG blockade reverse these effects but result in decreased OXPHOS, and glucose restriction prevents DC activation, resulting in premature death of DCs (72).

This reprogramming of glucose metabolism, a switch from oxidative metabolism to glycolysis, is required for DC activation, phenotype maintenance, and migration to lymph nodes (73–75). DCs are rapidly activated by TLR signal heavily depends on a surge in glycolysis flux to fulfill metabolic and functional requirements (73), including the secretion of tumor necrosis factor-α (TNF-α), IL-6, and IL-12. Unlike conventional PI3K-dependent signaling, tumor necrosis receptor-associated factor family member associated NF-κB activator binding kinase 1 (also known as TBK1)/I-kappaB kinase ε-mediated Akt phosphorylation responds to lipopolysaccharide stimulation of TLRs in DCs (73). p-Akt/mTORC1 immediately promotes the transcription of HK2 and LDHA via HIF-1α (76). Subsequent HK2 upregulation and enrichment around the ion channels of mitochondria assist DCs to prime T cells in the microenvironment (73). Supplementing 2-DG into the DC culture mixture in vitro significantly weakened the ability to alter shape and remodel the cytoskeleton (74). Even the compensatory supply of ATP by mitochondrial OXPHOS could not reverse the decline in overall distance traveled and velocity (74). It has been proven that cxc chemokine receptor 7-mediated HIF-1α induction contributes to DC migration (74, 75).

Immature DCs exhibit a phenotype with lower cross-expression capacity (histocompatibility complex I and II) and lower expression of co-stimulatory molecules (CD80, CD86, and CD40) than mature DCs, which confers tolerance characteristics (i.e., tolerant DCs) in the peripheral immune system (77). Tolerant DCs exhibit significantly enhanced catabolic pathways, including OXPHOS and fatty acid oxidation, compared with the marked pro-inflammatory activity of activated DCs (also known as immunogenic DCs). Mitochondrial oxidative activity, ROS
production, and superoxide production are more pronounced in tolerant DCs (78). The extracellular acidification rate (mpH/min) analysis can indicate the rate, capacity, and reserves of glycolysis. Although tolerant and immunogenic DCs exhibited similar rates of glycolysis, tolerant DCs demonstrate higher glycolytic capacity and reserves, and therefore have higher ATP reserves (78). In contrast, tolerant DCs exhibit more active fatty acid oxidation than immunogenic DCs. Inhibition of fatty acid oxidation inhibits the functions of tolerant DCs and partially restores T-cell stimulation capacity (78).

GLYCOLYSIS IN AUTOIMMUNE DISEASES

The mechanism of hyperactivated glycolysis varies for different AIDs. Hallmark lesion sites represent not only differences in clinical symptoms but also differences in metabolic abnormalities. For example, expression signatures in III/IV lupus nephritis tubulointerstitium exhibit down-regulated glycolytic activity (79) while increased glucose uptake and glycolysis are observed in RA-lesioned joints (80). Additionally, glycolysis in diverse stages contributes to the development of AIDs. In the early stage of RA, naïve T cells demonstrate reduced phosphofructokinase-1 activity, a deficiency of glycolysis-derived ATP, and increased cell death (81). In the late stage of RA, up-regulated GLUT1 in synovial cells of joint tissue furthers HIF-1α function (82). Therefore, blockade of hypermetabolic states and inhibition of glycolytic mediators may be therapeutically useful for AIDs. In this section, we will review the primary features of glycolysis and innate immune cells in AIDs (as shown in Table 1), referring to the association between glycolysis and innate immune cell function.

SLE

Neutrophils contribute to SLE pathogenesis through multiple mechanisms, including the secretion of NETs, which are potent stimulators of type I IFN production. In SLE, neutrophil death and NETs formation are enhanced, leading to an increased debris burden associated with antinuclear autoantibodies (117–119). In healthy individuals, following uptake by macrophages, NETs are shuttled in phagosomes to lysosomes for degradation, and this process is promoted by DNase I and C1q (120). The authors showed that 62% of patients with SLE were serum positive for anti-DNase antibodies as opposed to 8% of healthy volunteers, suggesting that defects in the clearance of aberrant neutrophils by macrophages contribute to SLE pathogenesis (121). Moreover, the antimicrobial peptides and self-DNA composing the extracellular traps activate the plasmacytoid dendritic cells and autoimmune B cells via TLR9 engagement (122). IFN-α, a member of the type I interferon family, is majorly generated from plasmacytoid DCs in SLE (122).

The glycolytic key enzymes and metabolites are involved in the propensity to form NETs. Compared with that in neutrophils from healthy volunteers, the expression of GLUT-3 and GLUT-6 is reported to be decreased in the cell membranes of neutrophils from patients with SLE, along with a concomitant decrease in intracellular glucose concentration (83, 84). When intracellular glucose and glycolytic fluxes are declined to levels where neutrophil viability is difficult to maintain, B-cell lymphoma 2 apoptosis regulator-dependent apoptosis is activated and neutrophil numbers reduce (85). Besides, Perner et al. found that a deficiency of PPP-derived NAPDH was directly associated with reduced NADPH oxidase 2 activity and ROS production (86). Neutrophils may compensate for PPP-related ROS using mitochondrial-originated ROS. But all these changes result in reduced cellular redox capacity and oxidation of mitochondrial DNA (87). Oxidized DNA is subsequently expelled through the mechanism of NETs (87). Some scientists have revealed that neutrophils suffer from a distinct form of cell death, named NETosis, after releasing NETs (88, 89). NETosis has been indicated as an important cause of neutropenia in SLE (89). Although a recent study has revealed that ferroptosis (a novel kind of cell death related to iron overload and abnormal lipid metabolism) (123) may be the major contributor to neutropenia in SLE (124), it is undeniable that alteration of glycolytic activity is involved in the progression of this disease.

Similarly, single-cell RNA sequencing analysis of metabolism-related genes revealed decreased glycolysis and TCA cycling but increased OXPHOS in lupus nephritis renal epithelial clusters (79). The proximal tubule cells have more mitochondria than other renal epithelial cells and are therefore dependent on oxidative metabolism, which prompts the renal epithelium in lupus nephritis to develop such a metabolic switch (79). Additionally, peroxisome biogenesis signatures were markedly upregulated in proximal tubule cells, suggesting that disease progression results in altered mitochondrial and peroxisomal metabolism (79). The simultaneous administration of the mitochondrial metabolism inhibitor metformin and glycolysis inhibitor 2-DG significantly restored immune tolerance of lupus mice, dampening autoimmune inflammation. These findings indicate that immunometabolic regulation may be a practical strategy for SLE therapy (125).

Conversely, activated glycolysis regulates the functions of T cells involved in SLE pathogenesis. Glutaminase Gls1 promotes HIF-1α expression and glycolytic activity, enabling the differentiation of CD4+ T cells into T helper (Th) 17 cells to promote SLE disease activity (126). Aberrant tryptophan metabolites are the mediators that manipulate CD4+ T cells to produce IFN-γ, which contributes to the development of lupus nephritis tubulointerstitial inflammation. In an in vitro assay, kynurenine induces mTORC1 activity in double negative T cells but not in CD4+ or CD8+ T cells derived from human (43). Interestingly, kynurenine enhances CD4+ T cells to produce IFN-γ in lupus-prone mice, whereas tryptophane stimulates mTORC1 signaling and glycolytic activity in CD4+ T cells (129). It has been proven that gut microbiota predominantly growing in SLE contributes to this aberrant tryptophan metabolism (128, 129). IDO levels are higher in SLE patients (130) and are associated with the active phenotype in the sunny season (131). In response to inflammation, IDO is often highly expressed by antigen-presenting cells (such as macrophages and DCs) that appear specialized for rapid response (132). IL-1β

Frontiers in Immunology | www.frontiersin.org
July 2022 | Volume 13 | Article 920029

Xu et al. Glycolysis Contributes to Autoimmunity
alone with IDO-1 is identified as hyperactivated in autoimmune macrophages (42, 133). M1-like macrophages may be involved in generating kynurenine and modulating T-cell immunity. Besides, inhibition of kynurenine 3-hydroxylase results in decreased intracellular catabolism of kynurenine, which is driven by enhanced PPP (43). Importantly, increased PPP transcription is closely associated with CD68+ macrophages in the lupus kidney and is to blame for the reduced glomerular filtration rate (134). All of these show that oxidative stress in macrophages promotes kynurenine accumulation.

### TABLE 1 | The primary features of glycolysis and innate immune cells in AIDs.

| Disease                        | Innate immune cell | Glycolysis activity | Mechanism                                                                 | Reference |
|--------------------------------|--------------------|---------------------|---------------------------------------------------------------------------|-----------|
| Systemic Lupus Erythematosus   | Neutrophil         | Down                | 1) The expression of GLUT-3 and GLUT-6 is decreased on the cell membranes of neutrophils in patients with SLE. | (83–89)   |
|                                | Monocyte/Macrophage| Up                  | 2) Deficiency of PPP leads to reduced NOX2 activity and ROS production. Reduced cellular redox capacity and oxidation of mitochondrial DNA initiates NETs and neutrophil death. | (42, 43, 68, 90–93) |
|                                |                    |                     | 1) Macrophages undergo a switch to glycolysis in response to IgG immune complex stimulation, which is regulated by Syk/Erk/mTOR/HIF-1α and Syk/P38K/Akt/mTOR/HIF-1α signal. |           |
|                                |                    |                     | 2) Glycolysis-dependent IL-1β production in macrophages leads to neutrophil recruitment and exacerbation of lupus nephritis. |           |
|                                | Dendritic cell     | Up                  | 3) Hdac7 maintains PKM2 activity in macrophages via histone deacetylation. Hdac7 gene is considered a susceptibility loci for SLE. |           |
| Rheumatoid Arthritis           | Neutrophil         | Up                  | 4) PKM2 expression is highly expressed in monocytes, DCs, and B cells derived from patients with SLE, compared to those derived from healthy volunteers. A PKM2–MAPK/NF-κB-PKM2 feedback loop is activated in these cells in spontaneous lupus MRL/lpr mice and mycophenoid-induced lupus mice. |           |
|                                | Monocyte/Macrophage| Up                  | 5) Enhanced PPP in macrophage inhibits kynurenine 3-hydroxylase, resulting in kynurenine accumulation. Kynurenine stimulates the mTORC1 activity in human T cells. | (90)      |

### References:

1. Systemic Lupus Erythematosus, SLE; Glucose transporter, GLUT; Pentose phosphate pathway, PPP; Nicotinamide adenine dinucleotide phosphate, NADPH; NADPH oxidase 2, NOX2; Reactive oxygen species, ROS; Neutrophil extracellular traps, NETs; Pyruvate kinase isoenzyme M2, PKM2; Phosphatidylinositol 3 kinase, PI3K; Serine-threonine protein kinase, Akt; Copper metabolism domain containing 1, COMMD1; Receptor activator of nuclear factor kappa-B ligand, RANKL; E2F1, E2F transcription factor 1; Matrix metalloproteinase, MMP; Anti-cyclic citrullinated peptide antibody, anti-CCP; Tumor necrosis factor-α, TNF-α; Fibroblast-like synovocyte, FLS; Anti-neutrophil cytoplasmic antibody-associated vasculitis, AAV; Myeloperoxidase, MPO.
Recently, the glycolytic propensity in macrophages may have facilitated the inflammatory features of SLE. A study has found that human and mouse macrophages undergo a glycolytic switch in response to IgG IC stimulation, reflecting changes in macrophage metabolism in inflamed tissues in vivo (68). This metabolic reprogramming contributes to the production of many pro-inflammatory mediators, including IL-1β, which is further regulated by mTOR and HIF-1α. Inhibition of glycolysis or knockdown of HIF-1α attenuates IgG IC-induced macrophage activation in vitro, including in primary human kidney macrophage cell lines (68). Additionally, inhibition of glycolysis in a mouse model of antibody-mediated nephritis resulted in decreased renal macrophage IL-1β levels and decreased neutrophil recruitment (68).

PKM2 regulates the final step of glycolysis. PKM2 expression is reported to be higher in monocytes, DCs, and B cells derived from patients with SLE than in those derived from healthy volunteers (90). Additionally, a PKM2-MAPK/NF-κB-PKM2 feedback loop was reported in spontaneous lupus MRL/lpr mice and imiquimod-induced lupus mice (90). PKM2 inhibitors suppress proline-rich tyrosine kinase 2, preventing TLR4/TLR7/TLR9 from activating the MAPK/NF-κB pathway (90). PKM2 and lactate levels were reported to be abnormally increased in the hippocampus of MRL/lpr lupus mice (91). PKM2-β-catenin signaling leads to neuronal synapse loss by promoting microglial hyperactivation, hypersecretion of IL-6 and IL-1β, and hyperphagocytosis. In vivo application of AAV9-shPKM2 in a neuropsychiatric SLE mouse model was shown to delay cognitive impairment and brain damage (91). Hdac7, a histone deacetylase, prevents acetylation from limiting PKM2 expression in macrophages (92). Mouse bone marrow-specific deficient hdac7 can disrupt glycolysis-dependent inflammatory responses (92). Hdac7 is considered a susceptibility loci for SLE (93). These pieces of evidence reveal that, differing from neutrophils, controlling the glycolytic mechanism in macrophages may be a novel metabolic regulatory strategy for SLE treatment.

**RA**

The metabolic microenvironment of RA exhibits different characteristics at different stages and disease sites (81). In the first stage of RA, T cells lose self-tolerance, a critical function, and facilitate autoantibody production by B cells (135). A switch in the metabolic profile within immune cells is the primary mechanism at this stage. In the second stage, autoantibodies cause metabolic alterations in synovial cells, causing uncontrolled inflammation in the joint (135). Adaptive autoimmunity initiates abnormal innate immune functions in the third stage (135).

Increasing evidence suggests metabolic feature changes in stromal and immune cells in RA (136). Recent studies have shown that the hexokinase 2 (HK2) level is elevated in Th17, DC, and fibroblast-like synoviocyte (FLS). By inhibiting glycolysis-dependent DCs activation and Th17/Treg imbalance, specific inhibition of HK2 (3-bromopyruvate) significantly reduced the degree of joint swelling and histological damage in SKG mice (a RA model) (137). Upregulation of HK2 is associated with hypertrophy of the synovial lining, which is involved in the bone and cartilage damage observed in RA (138). Hyperactivated HK2 promotes the proliferation and secretory function of synovial cells by mediating AMPK to activate NF-κB signaling (139). HK2 inhibitors effectively restrain the production of inflammatory factors (140). Additionally, AMPK can limit the activity of mTORC1 in immune cells. Wen et al. showed that dysfunctional AMPK induces hyperactive glycolysis in helper T cells by mediating aberrant activation of mTORC1, which facilitates the exacerbation of synovitis in RA (141). Citrate synthase levels decrease in RA synovial fluid, which suggests that the anaerobic glycolytic activity in the joint is upregulated under hypoxic conditions (142). Additionally, lactate levels in the blood samples of patients with early RA correlate with the degree of inflammation (143). Synovial fluid metabolomics in patients with RA demonstrated decreased glucose and increased lactate levels, which correlated with disease activity and markers, such as C-reactive protein (143). GLUT1 is the major glucose transporter in RA-FLSs, macrophages, and T cells. Upregulation of GLUT1 has been reported in the lining and sublining of the RA synovium (82). GLUT1 is also associated with increased glucose uptake and a hypoxic microenvironment in the joints with increased HIF-1α activity (144).

A recent study provided new insights into how glycolysis in innate immune cells contributes to RA progression. Using [18F]-fluoro-2-deoxy-d-glucose ([18F]FDG)-positron emission tomography-computed tomography tracing, Kubota et al. reported that increased glucose uptake in patients with RA correlated with disease severity and treatment response (145). Higher levels of [18F]FDG accumulation in swollen joints are associated with pannus rather than periarticular infiltration of inflammatory cells and are positively associated with arthritis progression (146). This observation suggests that activated macrophages contribute to the accumulation of [18F]FDG in the pannus, with hypoxia and cytokine stimulation promoting [18F]FDG uptake by macrophages.

Depending on glucose uptake and NADPH flux, NET induction is strongly correlated with joint damage and the pathogenesis of RA. The formation of anti-cyclic citrullinated peptide antibodies (anti-CCPs) and rheumatoid factor in the peripheral blood is a characteristic phenomenon of RA (94, 95). The citrullinated self-antigens recognized by anti-CCP are produced by peptidyl arginine deiminase (PAD) (94, 95). Neutrophils express aberrant levels of PAD in the synovial fluid of RA patients (94, 96). This is proved by the evidence that the PAD alone with myeloperoxidase (MPO) is located in the necrotic areas of synovial tissue (97). Aggrandized NETs are detected in the neutrophils from circulating, synovial tissue (98) and rheumatoid nodules in RA, which exhibit a correlation with anti-CCP levels (99). NETs formation is triggered by co-engagement of anti-CCP, IL-17A, and TNF-α (99). Subsequently, NETs induce further pro-inflammatory activity (including secretion of IL-6 and IL-8) in FLSs (99). Various proteins in NETs can damage the cartilage matrix and aggravate joint damage, including elastase and matrix metalloproteinase (2, 8, and 9) (100, 101, 147). Among them, elastase can promote the release of PAD2 from FLSs, which can citrullinate cartilage fragments (101). FLS phagocytose modified cartilage fragments (autoantigens), present antigens and induce autoimmune CD4+ T cells (101).
Both undifferentiated monocytes and macrophages in RA are in a hypermetabolic state (148). IL-1β, which is a consequence of metabolic reprogramming, seems to be a vital contributor to the pathogenesis of RA (102–108). Cinnamaldehyde inhibits the expression of the succinate receptor 1 and the accumulation of succinate, leading to restricted HIF-1α activation and ultimately limiting glycolytic activity (102). Inhibitors of TLR7 and IL-1 receptor-associated kinase 4 also interrupt HIF-1α/c-Myc signaling (103). Impairing macrophage glycolysis in RA is associated with inflammasome disassembly, decreased IL-1β production, and arthritis remission (102). The cellular membrane zinc transporter Zip8 is reported to be present at higher levels in the synovial tissue of patients with RA than in healthy volunteers (104). Bioavailable zinc in the monocyte cytoplasm is essential for protein phosphatase 2 phosphatase activator inhibition and mTORC1/p-S6K phosphorylation. Zip8 expression is associated with IL-1β production in monocytes/macrophages in severe arthritis (104). Immunostaining confirmed that glycogen synthase kinase 3β expression is prevalent in macrophages in the RA-injured synovium, and glycogen synthase kinase 3β inactivation is a metabolic switch that induces mitochondria in macrophages to use oxygen inefficiently to produce sufficient ATP (105). The resultant large amount of ATP maintains the activity of collagenase cathepsin K and promotes the production of IL-1β and IL-6 (105).

PKM2 may be a connection between glycolysis and activated macrophages in RA. PKM2 is an active enzyme involved in glycolysis in macrophages, and its dimerization depends on the intracellular ROS concentration (106). Hypermetabolic macrophages in RA accumulate ROS and activate the PKM2/STAT3 signaling pathway and transcription of IL-1β and IL-6 (106). Production of TNF-α and IL-1β is triggered by STAT1 under PKM2 stimulation in the induced RA model (Dark Agouti rats) (107). Although FLSs express higher levels of PKM2 than immune cells, obviously, FLSs extracellularly secrete a small amount. PKM2 in synovial fluid and plasma of RA patients originates from activated macrophages rather than FLSs (108). The released PKM2 facilitates macrophages to differentiate into osteoclasts involved in joint destruction (108). A hypoxic environment, active glycolysis, and massive secretion of inflammatory factors are characteristic of the macrophage-to-osteoclast transition in the RA synovium (109, 110). This process also involves a deficiency of inhibitory signals, including the copper metabolism domain-containing 1/receptor activator of the nuclear factor kappa-B ligand (RANKL) axis (110). Lack of regulation of NF-κB signaling and the transcription factor E2F1 are the primary drivers for the metabolic shift in osteoclasts (110).

**Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)**

AAVs are a heterogeneous group of AIDs characterized by impaired microvasculature (149). Most of autoantibodies in most patients with ANCA-AAV are directed against autoantigens in the primary granules of neutrophils and lysosomes of monocytes, including MPO and protease 3. Patients with different autoantibodies exhibit different clinical manifestations. Patients with anti-protease 3 antibodies present with granulomatous inflammation, while patients with anti-MPO often present with sclerosis (149). Studies have reported that cross-linked ANCA Fab regions may be involved in disease progression by activating neutrophil superoxide production and inducing respiratory bursts (150, 151). Additionally, ANCA can induce NETs formation and simultaneously promote histone citrullination, which triggers disseminated intravascular coagulation, leading to toxic damage to the endothelium (111). This can be prevented by binding recombinant thrombomodulin to neutrophils via the macrophage 1 antigen (111). As mentioned earlier, lactate and G6P-dependent-PPP support the NET formation (31, 33, 34). These results indicate the crucial role of glycolysis in AAV.

Few studies have focused on the pathogenic role of monocytes in AAV. Recently, some evidence has found clues to how glycolysis in monocytes contributes to AAV development. It has also been suggested that ANCA F(ab)2, but not intact ANCA IgG, activates the respiratory burst of monocytes involved in AAV pathogenesis (152). The anti-MPO antibody stimulates monocyte differentiation into macrophages through macrophage-colony stimulating factor 1 (112), downregulates IL-10 secretion (113), and upregulates the secretion of several M1-like cytokines, such as IL-1β, IL-6, and IL-8 (114). Pro-inflammatory macrophages play a significant role in microvascular-targeted inflammation in AAV. O’Brien et al. reported that the metabolic transition of monocytes occurs after ANCA stimulation (115). Anti-MPO-stimulated monocytes exhibited massive uptake of glucose, increased glycolysis and OXPHOS (115). Glycolysis was also activated in anti-protease 3-stimulated monocytes, albeit for a shorter duration. Additionally, OXPHOS induces the subsequent secretion of IL-1β (115).

**Ankylosing Spondylitis (AS)**

AS refers to a group of diseases called spondyloarthopathies that present with chronic back pain predominantly affecting the spine and sacroiliac joints, the diagnosis of which is often delayed (153, 154). Genetic factors (153) and environmental factors, including smoking and infection (154), are the main risk factors for AS development; however, the exact mechanisms underlying AS pathogenesis are unclear. Ou et al. established a serum metabolism-associated diagnostic panel and found 55 metabolites that were significantly different between patients with AS before and after TNF inhibitor treatment (116). Healthy volunteers and patients with AS could be differentiated using five metabolites: L-glutamic acid, arachidonic acid, L-phenylalanine, phosphocholine [18:1(9Z)/18:1(9Z)], and 1-palmitoyleglycerol (area under the curve 0.998, 95% confidence interval: 0.992–1.000) (116). Pathway analysis showed that multiple pathways, including amino acid biosynthesis, glycolysis, glutaminolysis, fatty acid biosynthesis, and choline metabolism, were significantly active in patients with AS (116). This study provided new insights into AS pathogenesis; however, more mechanical studies investigating the role of immunometabolism in AS are required.
ANTI-GLYCOLYSIS DRUGS THAT TARGET INNATE IMMUNE CELLS

One possible use of metabolically targeted therapy is as an “adjuvant” to increase the effectiveness of co-administered biological or conventional antirheumatic drugs. Multiple pathways affect innate immune cells through different mechanisms that alter multiple aspects of the immune system and synergistically reduce the production and release of pro-inflammatory cytokines. Due to their cost-effectiveness and efficacy in metabolic reprogramming, many anti-malarial drugs, such as hydroxychloroquine and chloroquine, are also used to treat rheumatic diseases. While glycolysis plays a key role in activated FLSs, lactate levels in the FLSs of patients with RA are higher than those in the synovial fluid of patients with osteoarthritis (155). Increasing the reliance of immune cells on accelerated glycolysis makes them more vulnerable to apoptosis (155). This suggests that the biological mechanisms of metabolism-targeted drugs and their therapeutic effects deserve attention. In the section below, we review the molecular mechanisms of these drugs and their corresponding clinical applications.

Rapamycin

mTOR is recognized as a central regulator of multiple metabolic pathways that control cell differentiation, death, and inflammatory activity. mTOR activity mediated by various kinase signals upregulates the expression of glycolytic and inflammatory genes, which in turn helps immune cells meet metabolic demands (156). Given the role of mTOR signaling in regulating inflammation, it serves as a critical link between metabolic phenotypes and AIDs.

Notably, as an mTORC1 inhibitor, N-acetylcysteine can safely reduce disease activity in patients with SLE by suppressing T-cell inflammatory factors (157). Lupus nephritis is a comorbidity in late-stage SLE. Rapamycin treatment reduced renal tissue damage and proteinuria, improved renal function, and prolonged survival in NZBW/F1 lupus-prone mice (158). Aberrant elevation in antiphospholipid antibodies is thought to be associated with liver damage in SLE (159). Rapamycin can restore liver mitochondrial function by targeting mTORC1 and effectively reducing anti-β2-glycoprotein I and anticardiolipin in SLE mice (159).

Previous evidence suggests that controlling Th17-triggered inflammation is the mechanism by which rapamycin treats SLE. KN-93 can restrain Th17 differentiation by inhibiting the calmodulin-dependent protein kinase IV/Akt/mTOR pathway and reduce disease damage in SLE mice (160, 161). A recent study found that the HIF1α-dependent glycolytic pathway in macrophages can exacerbate IgG deposition-induced lupus nephritis (68). PI3K- and Erk-mediated mTOR hyperactivation increases HIF1α transcriptional activity (68). MRL-lpr mice treated with rapamycin exhibited a decline in neutrophil recruitment, IL-1β, prostaglandin E2, and ROS secreted from macrophages (68). These results suggest a potential therapeutic application of rapamycin in targeting macrophages for SLE therapy.

In a single-arm, open-label, phase 1/2 trial of sirolimus (rapamycin) in patients with active SLE, both the British Isles Lupus Assessment Group score and the SLE Disease Activity Index decreased significantly after 12 months of treatment (162). The drug had no adverse effects on liver function or lymphocyte count. In another trial of pediatric patients with SLE, most achieved durable remission with sirolimus treatment (163). Moreover, sirolimus has greater advantages for serological reduction and glucocorticoid tapering, compared to the classic immunosuppressant tacrolimus, in treating SLE (164).

Everolimus is a 40-O-(2-hydroxyethyl) derivative of rapamycin (165). By inhibiting mTOR signaling to block IL-2 activation in T cells, everolimus prevents T-cell hyperactivation and reduces arthritis activity in patients with RA. Patients with RA treated with everolimus for 12 weeks (36.1%) had significantly higher rates of pain reduction and decreased disease activity than those treated with placebo (16.7%) (165). However, the everolimus-treated group showed more fluctuating liver function and blood lipid levels. Another mTOR inhibitor, sirolimus, relieves RA symptoms while it exhibits no impact on routine blood tests and liver and renal functions (166, 167). Additionally, an ongoing clinical trial is evaluating the efficacy of temsirolimus (a mTORC1 inhibitor; ClinicalTrials.gov identifier: NCT00076206) in patients with active RA on concomitant methotrexate therapy. These data demonstrate the potential use of rapamycin for RA treatment.

Dimethyl fumarate

Dimethyl fumarate (DMF), an electrophilic, cell-permeable derivative of the TCA cycle metabolite fumarate, has been clinically approved as an immunomodulatory drug for treating multiple sclerosis (168). An increasing number of studies have reported that DMF mitigates the progression of AIDs by exerting effects on innate immune cells. DMF can succinylate the glycolytic enzyme GAPDH by covalently modifying cysteine residues. DMF can reportedly reduce GAPDH activity, inhibit aerobic glycolysis in bone marrow-derived cells and lymphocytes, and exert anti-inflammatory effects, both in vitro and in vivo (169). DMF reciprocally inhibits the survival, differentiation, and effector functions of Th1 and Th17 cells while promoting the development of regulatory T cells. Therefore, DMF selectively targets effector cells while sparing regulatory and naive T cells (170).

DMF induces nuclear translocation of nuclear factor E2-related factor 2 (Nrf2) and enhances Nrf2 promoter activity while attenuating RANKL-mediated intracellular ROS generation (171). The latter is an osteoclast effector that inhibits RANKL-induced bone destruction (171). Activation of Nrf2 in osteoclasts/macrophages by DMF inhibits bone and joint destruction in patients with RA (171). Additionally, DMF inhibits MAPK signaling, thereby downregulating RANKL-induced expression of c-Fos, calcineurin-dependent 1, and nuclear factor of activated T cell cytoplasmic-1 (172). DMF disrupts actin ring formation by inhibiting the abovementioned signaling pathways,
ultimately inhibiting the pit-forming activity of osteoclasts (172). DMF inhibits the extracellular release of high-mobility group box 1 by activating Nrf2. Simultaneously, DMF reduces the phosphorylation of p38 MAPK and extracellular signal-regulated kinase in osteoclasts (173). Additionally, DMF succinylates IL-1 receptor-associated kinase 4 in plasmacytoid DCs, preventing the binding of IL-1 receptor-associated kinase 4 to the adaptor protein MyD88 and decreasing the inflammatory cytokines IL-1, IL-18, INF-α, and TNF-α (174). Plasmacytoid DCs are activated in SLE and accumulate in the skin and produce interferons (175). DMF is potentially an important regulator of the innate immune response and may be a novel treatment strategy for SLE.

**Hexokinase Inhibitors**

Hexokinase can catalyze the phosphorylation of glucose, initiating the glycolysis process. Owing to its structural similarity to glucose, 2-DG can competitively bind to HK2, inhibiting HK2 production by accumulation of phosphorylated 2-DG (176). In pre-clinical experiments, 2-DG significantly attenuated arthritis progression and reduced adaptive and innate immune cell activation in K/BxN mice (176). Cai et al. reported that inducible-nitric oxide synthase expressing M1 macrophages are significantly increased in arthritic joints and that 2-DG can effectively induce arginase 1 expressing M2 macrophages via the AMPK/NF-κB axis (177). Lonidamine, an inhibitor of HK1 and HK2, attenuates joint destruction in collagen-induced arthritis mice (178). The suppression of HK1 and HK2 downregulates the IL-1β and TNF-α expression and restores the anti-inflammatory activity of macrophages in the RA model. Currently, lonidamine and 2-DG are used in phase I/II trials for treating advanced cancers (179). The investigators observed only minor adverse effects, including nausea and blood glucose reduction (179).

**Metformin**

Metformin was initially used in the first-line treatment of type 2 diabetes owing to its safe glucose-lowering effect (180). Increasing studies have taken advantage of the metabolism modulation property of metformin for treating various diseases, including cancer, cardiovascular disease, and AIDs (180). Metformin can modulate immunometabolism by mediating AMPK signaling. AMPK/mTOR is involved in the differentiation of CD4+ T cells (181). The expression of transcription factors, especially STAT, mediates mTORC1-dependent Th17 differentiation, which contributes to the development of RA (182). Additionally, metformin-activated AMPK suppresses the function of STAT3 and NF-κB, and boosts macrophages to exhibit an anti-inflammatory phenotype (183). In an Israeli cohort, patients on high-dose (2,550 mg/day) metformin had a lower risk of developing RA than those on low-dose (850 mg/day) metformin (adjusted hazard ratio of 0.62, 95% confidence interval 0.46–0.84), especially in women (184). A randomized controlled trial shows that RA patients treated with metformin for 12 weeks (80.8%) had significantly higher rates of pain reduction and decreased disease activity than those treated with placebo (54.7%) (185). No serious adverse effects were reported in these two groups.

Since glycolysis contributes to NETs formation, metformin reduced phorbol 12-myristate 13-acetate-induced NET formation via the AMPK/mTOR axis (186). NET-derived mitochondrial DNA induces IFNα production in pDCs, which is an important pathogenesis of SLE (186). Metformin with concomitant hydroxychloroquine in patients with mild or moderate SLE can reduce clinical flares and disease progression (186, 187).

**SUMMARY AND PROSPECT**

Uncontrolled inflammatory bursts are a common feature of AIDs, including SLE, RA, AS, and ANCA-AAV. Various studies have demonstrated that innate immune cells adapt their metabolism to maintain or change their inflammatory phenotype. Additionally, a growing body of evidence supports the immunomodulatory properties of glycolytic metabolites in AIDs. Molecule machines, such as mTOR, AMPK, and HK2, which were initially thought to be simply regulators of cellular metabolism, are now regarded as therapeutic targets for modulating inflammatory responses. Hence, the discovery that an immune metabolism characterized by glycolysis may regulate inflammation broadens the avenues for treating AIDs. Strategies to target the abovementioned signaling molecules can be developed to modulate immune cell metabolism. Therefore, additional studies are needed to increase our understanding of the metabolic pathways in innate immune cells that are involved in the pathogenesis of AIDs, could potentially be exploited therapeutically to weaken exacerbated inflammatory responses.

**AUTHOR CONTRIBUTIONS**

LC and FW contributed to support the conception of the review. YX and YC wrote the manuscript and prepared the figures and the table. XZ, JM, and YL read, discussed, and revised the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (62071011, 81788101), the Chinese Academy of Medical Science Innovation Fund for Medical Sciences (CIFMS) (2021-1-I2M-017, 2021-1-I2M-047, 2021-1-I2M-040, 2021-1-I2M-016, and 2021-1-I2M-026), the Capital’s Funds for Health Improvement and Research (2020-2-4019), and the Key Clinical Specialty Funding Project of Beijing.
REFERENCES

1. Stathopoulos C, Nikoloi D, Bertsias G. Immunometabolism: An Overview and Therapeutic Prospects in Autoimmune Diseases. *Immunotherapy* (2019) 11(9):813–29. doi: 10.2217/imt-2019-0002

2. Jung SM, Kim WU. Targeted Immunotherapy for Autoimmune Disease. *Immun Nat* (2022) 22(1):e9. doi: 10.4110/imn.2022.22.e9

3. Wardemann H, Yurasov S, Schafer A, Young JW, Meffe E, Nussenzenzw M. Predominant Autoantibody Production by Early Human B Cell Precursors. *Science* (2003) 301(5638):1574–7. doi: 10.1126/science.1068690

4. Anaya JM, Restrepo-Jimenez P, Ramirez-Santana C. The Autoimmune Ecology: An Update. *Curr Opin Rheumatol* (2018) 30(4):350–60. doi: 10.1097/BOR.0000000000000498

5. Yang Z, Matteson EL, Goronyz JI, Weyand CM. T-Cell Metabolism in Autoimmune Disease. *Arthritis Res Ther* (2015) 17:29. doi: 10.1186/s13075-015-0542-4

6. Lin X, Lu L. B Cell-Mediated Autoimmune Diseases. *Adv Exp Med Biol* (2020) 1254:145–60. doi: 10.1007/978-981-15-3532-1_1

7. Wang L, Wang FS, Gershwin ME. Human Autoimmune Diseases: A Comprehensive Update. *J Intern Med* (2015) 278(4):369–95. doi: 10.1111/j.1465-3946.2015.05586.x

8. Chen J, Liu C, Ye S, Lu R, Zhu H, Xu J. UPLC-MS/MS-Based Plasma Lipidomics Reveal a Distinctive Signature in Systemic Lupus Erythematosus Patients. *MedComm* (2020) 2021(2):269–78. doi: 10.1002/mco.2627

9. Fu X, Liu H, Huang G, Dai SS. The Emerging Role of Neutrophils in Autoimmune-Associated Disorders: Effector, Predictor, and Therapeutic Targets. *MedComm* (2020) 2021(2):402–13. doi: 10.1002/mco.2629

10. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. *J Gen Physiol* (1927) 6(6):519–30. doi: 10.1085/jgp.6.6.519

11. Warburg O, Guewen K, Geissler AW. Metabolism of Leukocytes. *Z Naturforsch B* (1958) 13B(8):515–6. doi: 10.1515/znb-1958-0806

12. Finlay DK. Regulation of Glucose Metabolism in T Cells: New Insight Into the Role of Phosphoinositide 3-Kinases. *Front Immunol* (2012) 3:247. doi: 10.3892/immunofi.2012.00247

13. Yin Y, Choi SC, Xu Z, Perry DJ, Sea H, Croker BP, et al. Normalization of Z17. Chou WC, Rampanelli E, Li X, Ting JP. Impact of Intracellular Innate Immune Receptors on Immunometabolism. *Cell Metab* (2017) 26(1):51–61. doi: 10.1016/j.cmet.2017.06.019

14. Warburg O, Guewen K, Geissler AW. Metabolism of Leukocytes. *Z Naturforsch B* (1958) 13B(8):515–6. doi: 10.1515/znb-1958-0806

15. Finlay DK. Regulation of Glucose Metabolism in T Cells: New Insight Into the Role of Phosphoinositide 3-Kinases. *Front Immunol* (2012) 3:247. doi: 10.3892/immunofi.2012.00247

16. Lin X, Lu L. B Cell-Mediated Autoimmune Diseases. *Adv Exp Med Biol* (2020) 1254:145–60. doi: 10.1007/978-981-15-3532-1_1

17. Wang L, Wang FS, Gershwin ME. Human Autoimmune Diseases: A Comprehensive Update. *J Intern Med* (2015) 278(4):369–95. doi: 10.1111/j.1465-3946.2015.05586.x

18. Chen J, Liu C, Ye S, Lu R, Zhu H, Xu J. UPLC-MS/MS-Based Plasma Lipidomics Reveal a Distinctive Signature in Systemic Lupus Erythematosus Patients. *MedComm* (2020) 2021(2):269–78. doi: 10.1002/mco.2627

19. Xin X, Liu H, Huang G, Dai SS. The Emerging Role of Neutrophils in Autoimmune-Associated Disorders: Effector, Predictor, and Therapeutic Targets. *MedComm* (2020) 2021(2):402–13. doi: 10.1002/mco.2629

20. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. *J Gen Physiol* (1927) 6(6):519–30. doi: 10.1085/jgp.6.6.519

21. Warburg O, Guewen K, Geissler AW. Metabolism of Leukocytes. *Z Naturforsch B* (1958) 13B(8):515–6. doi: 10.1515/znb-1958-0806

22. Finlay DK. Regulation of Glucose Metabolism in T Cells: New Insight Into the Role of Phosphoinositide 3-Kinases. *Front Immunol* (2012) 3:247. doi: 10.3892/immunofi.2012.00247

23. Yin Y, Choi SC, Xu Z, Perry DJ, Sea H, Croker BP, et al. Normalization of CD4+ T Cell Metabolism Reverses Lupus. *Sci Transl Med* (2015) 7(274):274ra18. doi: 10.1126/scitranslmed.aao8035

24. Puleston DJ, Villa M, Pearce EL. Ancillary Activity: Beyond Core Metabolism in Immune Cells. *Cell Metab* (2017) 26(1):31–41. doi: 10.1016/j.cmet.2017.06.019

25. Pearce EL, Paffenberger MC, Chang CH, Jones RG. Fueling Immunity: Insights Into Metabolism and Lymphocyte Function. *Science* (2013) 342(6155):1242454. doi: 10.1126/science.1242454

26. Mills EL, Kelly B, O’Neill LAJ. Mitochondria Are the Powerhouses of Immunity. *Nat Immunol* (2017) 18(5):488–98. doi: 10.1038/nmi.3704

27. Chou WC, Rampanelli E, Li X, Ting JP. Impact of Intracellular Innate Immune Receptors on Immunometabolism. *Cell Mol Immunol* (2022) 19(3):337–51. doi: 10.1084/jci4122-001-00778-y

28. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, et al. Pyruvate Kinase M2 Regulates Hif-1alpha Activity and IL-1beta Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages. *Cell Metab* (2015) 21(1):65–80. doi: 10.1016/j.cmet.2014.12.005

29. Wang T, Jiao Y, Zhang X. Immunometabolic Pathways and Its Therapeutic Implication in Autoimmune Diseases. *Clin Rev Allergy Immunol* (2021) 60(1):55–67. doi: 10.1007/s12120-020-08821-6

30. Ryan K, Tekwani BL. Current Investigations on Clinical Pharmacology and Therapeutics of Glucose-6-Phosphate Dehydrogenase Deficiency. *Pharmacol Ther* (2021) 222:107788. doi: 10.1016/j.pharmthera.2020.107788

31. Breton J, Avanzi N, Magagnin S, Covini N, Magistrelli G, Cozzi L, et al. Functional Characterization and Mechanism of Action of Reombinant Human Kynurenine 3-Hydroxylase. *Eur J Biochem* (2000) 267(4):1092–9. doi: 10.1046/j.1432-1030.2000.01104.x

32. Saravia J, Raynor JL, Chapman NM, Lim SA, Chi H. Signaling Networks in Immunometabolism. *Cell Res* (2020) 30(4):328–42. doi: 10.1038/s41422-020-0301-0
Xu et al. Glycolysis Contributes to Autoimmunity

42. Mohammadi S, Saghaei-Jazi M, Sedighi S, Memarian A. Sodium Valproate Modulates Immune Response by Alternative Activation of Monocyte-Derived Macrophages in Systemic Lupus Erythematosus. *Clin Rheumatol* (2018) 37(3):719–27. doi: 10.1007/s10067-017-2922-0

43. Perl A, Hanczko R, Lai ZW, Oza K, Kelly R, Borusik R, et al. Comprehensive Metabolome Analyses Reveal N-Acetylcycteine-Responsive Accumulation of Kynurenine in Systemic Lupus Erythematosus: Implications for Activation of the Mechanistic Target of Rapamycin. *Metabolomics* (2015) 11(5):1517–74. doi: 10.1007/s11306-015-0772-0

44. Liu Y, Xu R, Gu H, Zhang E, Qu J, Cao W, et al. Metabolic Reprogramming in Macrophage Responses. *BioMark Res* (2021) 9(1):1. doi: 10.4103/0936-020-00251-y

45. Tao J, Wang H, Ni M, Wang Z, Wang Z, Wei S, et al. FSTL1 Promotes Liver Fibrosis by Reprogramming Macrophage Function Through Modulating the Intracellular Function of PKM2. *Gut* (2022) gutjnl-2021-325150. doi: 10.1136/gutjnl-2021-325150

46. Timmons GA, Carroll RG, O'Siorain JR, Cervantes-Silva MP, Fagan LE, Cox SL, et al. The Circadian Clock Protein BMAL1 Acts as a Metabolic Sensor in Macrophages to Control the Production of Pro IL-1beta. *Front Immunol* (2021) 12:700043. doi: 10.3389/fimmu.2021.700043

47. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites. *Front Immunol* (2021) 12:704551. doi: 10.3389/fimmu.2021.704551

48. Kobayashi T, Nguyen-Tien D, Sorimachi Y, Sugira Y, Suzuki T, Karyu H, et al. SLC15A4 Mediates M1-Prone Metabolic Shifts in Macrophages and Guards Immune Cells From Metabolic Stress. *Guards Immune Cells From Metabolic Stress.*

49. Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic Instruction of the Kinases TBK1-

50. Timmons GA, Carroll RG, O'Siorain JR, Cervantes-Silva MP, Fagan LE, Cox SL, et al. The Circadian Clock Protein BMAL1 Acts as a Metabolic Sensor in Macrophages to Control the Production of Pro IL-1beta. *Front Immunol* (2021) 12:700043. doi: 10.3389/fimmu.2021.700043

51. Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites. *Front Immunol* (2021) 12:704551. doi: 10.3389/fimmu.2021.704551

52. Timmons GA, Carroll RG, O'Siorain JR, Cervantes-Silva MP, Fagan LE, Cox SL, et al. The Circadian Clock Protein BMAL1 Acts as a Metabolic Sensor in Macrophages to Control the Production of Pro IL-1beta. *Front Immunol* (2021) 12:700043. doi: 10.3389/fimmu.2021.700043

53. Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz P, et al. Substrate Fate in Activated Macrophages: A Comparison Between Immune Classic and Alternative Activation. *ImmunoLog* (2010) 185(1):605–14. doi: 10.4049/jimmunol.0901698

54. Vats D, Mukundan L, Odegaard JJ, Zhang L, Smith KL, Mored CR, et al. Oxidative Metabolism and PGC-1beta Attenuate Macrophage-Mediated Inflammation. *Cell Metab* (2006) 4(1):13–24. doi: 10.1016/j.cmet.2006.05.011

55. Wang F, Zhang S, Vuckovic I, Jeon R, Lerman A, Holmes CD, et al. Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation. *Cell Metab* (2020) 28(3):463–75 e4. doi: 10.1016/j.cmet.2018.08.012

56. Van Z, Xie N, Cui H, Moeller DR, Abraham E, Thannickal VJ, et al. Pyruvate Dehydrogenase Kinase 1 Participates in Macrophage Polarization via Regulating Glucose Metabolism. *J Immunol* (2015) 194(12):6802–9. doi: 10.4049/jimmunol.1402469

57. Van den Bosch J, Baarden J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages. *Cell Rep* (2016) 17(3):684–96. doi: 10.1016/j.celrep.2016.09.008

58. Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, et al. Akt-mTORC1 Signaling Regulates mTORC1's Ability to Inhibit Tunicamycin-Induced Changes in Glycolytic Metabolism Regulate Dendritic Cell Activation. *Blood* (2016) 128(19):2495–4950. doi: 10.1182/blood-2016-03-735572

59. Liu J, Zhang X, Chen K, Cheng Y, Liu X, Xia M, et al. CCC7 Chemokine Receptor-Inducible Inc-Dp3 Restains Dendritic Cell Migration by Inhibiting HIF-1alpha-Mediated Glycolysis. *Immunity* (2019) 50(3):600–15.e15. doi: 10.1016/j.immuni.2019.01.021

60. Boada-Romero E, Martinez J, Heckmann BL, Green DR. The Clearance of Dead Cells by Efferocytosis. *Nat Rev Mol Cell Biol* (2020) 21(7):398–414. doi: 10.1038/s41592-020-0232-1

61. Doran AC, Yardagul Al, Tuba I. Efferocytosis in Health and Disease. *Nat Rev Immunol* (2020) 20(4):254–67. doi: 10.1038/s41577-019-0204-6

62. Zhang S, Weinberg S, DeBerge M, Gainullina A, Schipma M, Kinchen JM, et al. Efferocytosis Fuels Requirements of Fatty Acid Oxidation and the Electron Transport Chain to Polarize Macrophages for Tissue Repair. *Cell Metab* (2019) 29(2):443–56.e5. doi: 10.1016/j.cmet.2018.12.004

63. Sembn H, Takeda N, Isagawa T, Sugira Y, Honda K, Wake M, et al. HIF-1alpha-PDK1 Axis-Induced Active Glycolysis Plays an Essential Role in Macrophage Migratory Capacity. *Nat Commun* (2016) 7:11635. doi: 10.1038/ncomms11635

64. Arts RIJ, Joosten LAB, Netea MG. The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders. *Front Immunol* (2018) 9:298. doi: 10.3389/fimmu.2018.00298

65. Cheng SC, Quintin J, Cramer RA, Sheikhson KM, Saeed S, Kumar V, et al. Glutaminolysis and Fumarate Accumulation in Immune and Epigenetic Programs in Trained Immunity. *Cell Metab* (2016) 24(6):807–19. doi: 10.1016/j.cmet.2016.10.008

66. Sim WJ, Ahl PJ, Connolly JE. Metabolism Is Central to Tolerogenic Dendritic Cell Function. *Cell Rep* (2018) 2016:2636701. doi: 10.1016/j.celrep.2016.09.016

67. Jing C, Castro-Dopico T, Richoz N, Tuong ZK, Ferdinand J, Lok LSC, et al. Macrophage Reprogramming Presents a Therapeutic Target in Lupus Nephritis. *Proc Natl Acad Sci USA* (2020) 117(26):1526084. doi: 10.1126/science.abd1250784

68. Bhunyakarnjanarat T, Udompornpitak S, Kaisorn W, Chantraprapawat P, Visitchanakan P, Dang CP, et al. Prominent Indomethacin-Induced Enteropathy in Fcgri IIb-Cient Lupus Mice: An Impact of Macrophage Responses and Immunodeposition in Gut. *Int J Mol Sci* (2021) 22(3):1377. doi: 10.3390/ijms22031377
Xu et al. Glycolysis Contributes to Autoimmunity

Phenotype of Human Tolerogenic Dendritic Cells. *J Immunol* (2015) 194 (11):5174–86. doi: 10.4049/jimmunol.1503316

Kingsmore KM, Bachali P, Catalina MD, Daamen AR, Heuer SE, Robl RD, et al. Altered Expression of Genes Controlling Metabolism Characterizes the Tissue Response to Immune Injury in Lupus. *Sci Rep* (2021) 11(1):14789. doi: 10.1038/s41598-021-93034-w

Wang H, Zhang N, Fang K, Chang X. 2-Deoxy-D-Glucose Alleviates Collagen-Induced Arthritis of Rats and Is Accompanied by Metabolic Regulation of the Spleen and Liver. *Front Immunol* (2021) 12:713799. doi: 10.3389/fimmu.2021.713799

Weyand CM, Goronzy JJ. Immunometabolism in Early and Late Stages of Rheumatoid Arthritis. *Nat Rev Rheumatol* (2017) 13(5):291–301. doi: 10.1038/nrrheum.2017.49

Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, et al. Glucose Transporter Expression on the Plasma Membrane of Resting and Activated White Blood Cells. *Eur J Clin Invest* (2007) 37(4):282–90. doi: 10.1111/j.1365-2362.2007.01786.x

Li KJ, Wu CH, Hsieh SC, Lu MC, Tsai CY, Yu CL. Deranged Bioenergetics and Defective Redox Capacity in T Lymphocytes and Neutrophils are Related to Cellular Dysfunction and Increased Oxidative Stress in Patients With Active Systemic Lupus Erythematosus. *Clin Dev Immunol* (2012) 2012:548516. doi: 10.1155/2012/548516

Maciver NJ, Jacobs SR, Wieman HL, Wolford JA, Coloff JL, Rathenell JC. Glycolysis Metabolism in Lymphocytes Is a Regulated Process With Significant Effects on Immune Cell Function and Survival. *J Leukoc Biol* (2008) 84 (4):949–57. doi: 10.1189/jlb.01080024

Perner A, Nielsen SE, Rask-Madsen J. High Glucose Impairs Superoxide Effects on Immune Cell Function and Survival. *Front Immunol* (2022) 13:840035. doi: 10.3389/fimmu.2022.840035

Chapman EA, Lyon MP, Monson D, Mason D, Beynam RJ, Moots RJ, et al. Caught in a Trap? Protemic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus. *Front Immunol* (2019) 10:423. doi: 10.3389/fimmu.2019.00423

Turunen S, Huhtakangas J, Nousiainen T, Valkealahti M, Melkko J, Risteli J, et al. Rheumatoid Arthritis Antigens Homocitrulline and Citrulline are Generated by Local Myeloperoxidase and Peptidyl Arginine Deiminases 2, 3 and 4 in Rheumatoid Nodule and Synovial Tissue. *Arthritis Res Ther* (2016) 18(1):239. doi: 10.1186/s13075-016-1140-9

Birkeland S, Bennike TB, Kastaniegaard K, Lausen M, Poulsen TBG, Kragstrup TW, et al. Protemic Analysis of Synovial Fluid From Rheumatic Arthritis and Spondyloarthritis Patients. *Clin Proteomics* (2020) 17:29. doi: 10.1186/s12014-020-09292-9

Khandpur R, Carvera-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. *Sci Transl Med* (2013) 5(178):178ra40. doi: 10.1126/scitranslmed.3005580

Carvera-Rivera C, Carlucci PM, Moore E, LINGampalli N, Uchenthen H, James E, et al. Synovial Fibroblast-Neutrophil Interactions Promote Pathogenic Autoimmune in Rheumatoid Arthritis. *Sci Immunol* (2017) 2(16):eaaq3358. doi: 10.1126/sciimmunol.aqa3358

Lee KH, Kronbichler A, Park DD, Park Y, Moon H, Kim H, et al. Class IIa Histone Deacetylases Drive Toll-Like Receptor-Inducible Extracellular Traps (NETs) in Autoimmune Diseases: A Comprehensive Review. *Autoimmun Rev* (2019) 18(11):1053–62. doi: 10.1016/j.jimmuni.2017-212647

Alquraishi M, Puckett DL, Alani DS, Hamidat AS, Frankel VD, Donohoe DR, et al. Pyruvate Kinase M2: A Simple Molecule With Complex Functions. *Sci Transl Med* (2015) 7(300):300ra91. doi: 10.1126/scitranslmed.aaa9916

Murata K, Fang C, Terao C, Giannopoulou EG, Lee YJ, Lee MJ, et al. Neutrophil Extracellular Traps Mediate Articular Cartilage Damage and Enhance Cartilage Component Immunogenicity in Rheumatoid Arthritis. *JCI Insight* (2020) 5(13):e139388. doi: 10.1172/jci.insight.139388

Kim B, Kim HY, Yoon BR, Yeo J, In Jung J, Yu KS, et al. Cytoplasmic Zinc Promotes IL-1beta Production by Monocytic and Macrophages Through mTORC1-Induced Glycolysis in Rheumatoid Arthritis. *Sci Signal* (2022) 15 (716):eabf7400. doi: 10.1126/scisignal.abf7400

Zeisbrich M, Yanes RE, Zhang H, Watanabe R, Li Y, Brosig L, et al. Hypermetabolic Macrophages in Rheumatoid Arthritis and Coronary Artery Disease Due to Glycogen Synthesis Kinase 3b Inactivation. *Ann Rheum Dis* (2018) 77(10):1783–92. doi: 10.1136/annrheumdis-2017-212647

Liu P, Wing J, Wen W, Pan T, Chen H, Fu Y, et al. Cinnamaldehyde Suppresses NLRP3 Derived IL-1beta via Activating Succinate/HIF-1 in Rheumatoid Arthritis Rats. *Int Immunopharmacol* (2020) 84:106570. doi: 10.1016/j.intimp.2020.106570

Umär S, Palasiewicz K, Volin MV, Zanotti B, Al-Awqati M, Sveiss N, et al. IRAK4 Inhibitor Mitigates Joint Inflammation by Rebalancing Metabolism Malfunction in RA Macrophages and Fibroblasts. *Life Sci* (2021) 287:120114. doi: 10.1016/j.lfs.2021.120114

Loo D, Huyn HT, Yoon BR, Yeo J, In Jung J, Yu KS, et al. Pyruvate Kinase M2: A Simple Molecule With Complex Functions. *Free Radic Biol Med* (2019) 143:176–92. doi: 10.1016/j.freeradbiomed.2019.08.007

Xu J, Jiang C, Wang X, Geng M, Peng Y, Guo Y, et al. Upregulated PKM2 in Macrophages Exacerbates Experimental Arthritis via STAT1 Signaling. *J Immunol* (2020) 205(1):181–92. doi: 10.4049/jimmunol.1901021

Han DW, Choi YS, Kim HW, Shin S, Ha YJ, Kang EH, et al. Extracellular Pyruvate Kinase M2 Promotes Osteoclastogenesis and is Associated With Radiographic Progression in Early Rheumatoid Arthritis. *Sci Rep* (2022) 12 (1):4024. doi: 10.1038/s41598-022-07667-6

Van Raemdonck K, Umar S, Palasiewicz, Volin MV, Ehlabrawy HA, Romay B, et al. Interleukin-34 Regulates Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor. *Arthritis Rheumatol* (2021) 73 (11):2003–14. doi: 10.1002/art.41792

Murata K, Fung C, Terao C, Giannopoulou EG, Lee YJ, Lee MJ, et al. Hypoxia-Sensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis. *Immunity* (2017) 47(1):66–79.e5. doi: 10.1016/j.immuni.2017.06.018

Watanabe-Kusunoki D, Nakazawa D, Kusunoki Y, Kudo T, Hattanda F, Nishiro S, et al. Reombinant Thrombomodulin Ameliorates Autoimmune Vasculitis via Immune Response Regulation and Tissue Injury Protection. *Autoimmun* (2020) 108:102390. doi: 10.1016/j.jaut.2019.102390
Xu et al. Glycolysis Contributes to Autoimmunity

Rheumatoid Arthritis. *Arthritis Res Ther* (2012) 14(5):R204. doi: 10.1186/ar4042

162. Lai ZW, Zeibisch M, Goronzy JJ. Metabolic Signatures of T-Cells and Macrophages in Rheumatoid Arthritis. *Curr Opin Immunol* (2017) 46:112–20. doi: 10.1016/j.coi.2017.04.010

164. van der Woude FJ, Rasmussen N, Lobatto S, Wikl A, Permin H, van Es LA, et al. Autoantibodies Against Neutrophils and Monocytes: Tools for Diagnosis and Marker of Disease Activity in Wegener's Granulomatosis. *Lancet* (1985) 1(8426):425–9. doi: 10.1111/j.1532-2634.1985.tb11417.x

165. Kettritz R, Jentette JC, Falk RJ. Crosslinking of ANCA-Antigens Stimulates Superoxide Release by Human Neutrophils. *J Am Soc Nephrol* (1997) 8(3):386–94. doi: 10.1681/ASN.1997030003b0002

166. Keogan MT, Esnault VL, Green AJ, Lockwood CM, Brown DL. Activation of Normal Neutrophils by Anti-Neutrophil Cytoplasm Antibodies. *Clin Exp Immunol* (1992) 90(2):238–34. doi: 10.1111/j.1365-2249.1992.tb07394.x

167. Weidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil Cytoplasmic Antibodies Induce Human Monocytes to Produce Oxygen Radicals *In Vitro*. *Arthritis Rheum* (2001) 44(7):1698–706. doi: 10.1002/1529-0131(200107)44:7<1698::AID-ART294>3.0.CO;2-J

168. Brown MA, Kenna T, Wordsworth BP. Genetics of Ankylosing Spondylitis: Tert, or Intolerant of, Conventional Medications: A Single-Arm, Open-Label, Randomised, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study. *Ann Rheum Dis* (2008) 67(8):1090–5. doi: 10.1136/ard.2007.078808

169. Niu HQ, Li ZH, Zhao WP, Zhao XC, Zhang C, Luo J, et al. Sirolimus Selectively Increases Circulating Treg Cell Numbers and Restores the Th17/Treg Balance in Rheumatoid Arthritis Patients With Low Disease Activity or in DAS28 Remission Who Previously Received Conventional Disease-Modifying Anti-Rheumatic Drugs. *Clin Exp Rheumatol* (2020) 38(1):58–66.

170. Wen HY, Wang J, Zhang SX, Luo J, Zhao XC, Zhang C, et al. Low-Dose Sirolimus Immunoregulation Therapy in Patients With Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial. *J Immunol Res* (2019) 2019:7684352. doi: 10.1155/2019/7684352

171. van Gleen F, Dias-Carneiro RPC, Moraes AS, Farias SA, Silva V, Oliveira FTM, et al. Dimethyl Fumarate Downregulates the Immune Response Through the HCA2/GPR19A Pathway: Implications for the Treatment of Multiple Sclerosis. *Mult Scler Relat Disord* (2018) 23:46–50. doi: 10.1016/j.msard.2018.04.016

172. Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, et al. Dimethyl Fumarate Targets GAPDH and Aerobic Glycolysis to Modulate Immune Activity. *Science* (2018) 360(6387):449–53. doi: 10.1126/science.aan4665

173. Nishioku T, Kawamoto M, Okizono R, Sakai E, Okamoto K, Tsukuba T. Dimethyl Fumarate Prevents Osteoclastogenesis by Decreasing NFATc1 Expression, Inhibiting of Erk and P38 MAPK Phosphorylation, and Suppressing of HMGB1 Release. *Biochem Biophys Res Comm* (2020) 530(2):455–61. doi: 10.1016/j.bbrc.2020.05.088

174. Zaro BW, Vinogradova EV, Lazar DC, Blewett MM,Suciu RM, Takaya J, et al. Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MYD88 Complex. *J Immunol* (2019) 202(9):2737–46. doi: 10.4049/jimmunol.1802465

175. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnson FL. Plasmacytoid Dendritic Cells (Natural Interferon-Alpha-Beta-Producing Cells) Accumulate in Cutaneous Lymphocytic Erythematous Lesions. *Am J Pathol* (2019) 191(1):237–43. doi: 10.1016/j.ajpath.2018.01.011

176. Abboud G, Choi SC, Kanda N, Zeumer-Spataro L, Roojenan DC, Morel L. Inhibition of Glycolysis Reduces Disease Severity in an Autoimmune Model of Rheumatoid Arthritis. *Front Immunol* (2018) 9:1973. doi: 10.3389/fimmu.2018.01973

177. Cai W, Cheng J, Zong S, Yu Y, Wang Y, Song Y, et al. The Glycolysis Inhibitor 2-Deoxyglucose Ameliorates Adjuvant-Induced Arthritis by Regulating Macrophage Polarization in an AMPK-Dependent Manner. *Mol Immunol* (2021) 140:186–95. doi: 10.1016/j.molimm.2021.10.007

178. Song G, Lu Q, Fan H, Zhang X, Ge L, Tian R, et al. Inhibition of Hexokinases Holds Potential as Treatment Strategy for Rheumatoid Arthritis. *Arthritis Res Ther* (2019) 21(1):87. doi: 10.1186/s13075-019-1865-3

179. Teng X, Cornaby C, Li W, Morel L. Metabolic Regulation of Pathogenic Autoimmunity: Therapeutic Targeting. *Curr Opin Immunol* (2019) 61:10–6. doi: 10.1016/j.coi.2019.07.001

180. Kim JW, Choi JY, Park SH. Metformin and its Therapeutic Applications in Autoimmune Inflammatory Disease. *Korean J Intern Med* (2022) 37(1):13–26. doi: 10.3904/kim.2021.363

181. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The Kinase mTOR Regulates the Differentiation of Helper T Cells
Through the Selective Activation of Signaling by mTORC1 and mTORC2.

Nat Immunol (2011) 12(4):295–303. doi: 10.1038/ni.2005

182. El-Sayyad SM, Ali MA, Kandil LS, Ragab GM, Abdelhamid Ibrahim SS. Metformin and Omega-3 Fish Oil Elicit Anti-Inflammatory Effects via Modulation of Some Dysregulated Micro RNAs Expression and Signaling Pathways in Experimental Induced Arthritis. Int Immunopharmacol (2021) 92:107362. doi: 10.1016/j.intimp.2020.107362

183. Zhou Z, Tang Y, Jin X, Chen C, Lu Y, Liu L, et al. Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly Through AMPK Activation and RAGE/NFκB Pathway Suppression. J Diabetes Res (2016) 2016:4847812. doi: 10.1155/2016/4847812

184. Naffaa ME, Rosenberg V, Watad A, Tiosano S, Yavne Y, Chodick G, et al. Adherence to Metformin and the Onset of Rheumatoid Arthritis: A Population-Based Cohort Study. Scand J Rheumatol (2020) 49(3):173–80. doi: 10.1080/03009742.2019.1695928

185. Abdallah MS, Alarfaj SJ, Saif DS, El-Naggar ME, Elsokary MA, Elsawah HK, et al. The AMPK Modulator Metformin as Adjunct to Methotrexate in Patients With Rheumatoid Arthritis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. Int Immunopharmacol (2021) 95:107575. doi: 10.1016/j.intimp.2021.107575

186. Wang H, Li T, Chen S, Gu Y, Ye S. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-Of-Concept Trial of Metformin. Arthritis Rheumatol (2015) 67(12):3190–200. doi: 10.1002/art.39296

187. Sun F, Geng S, Wang H, Wang H, Liu Z, Wang X, et al. Effects of Metformin on Disease Flares in Patients With Systemic Lupus Erythematosus: Post Hoc Analyses From Two Randomised Trials. Lupus Sci Med (2020) 7(1):e000429. doi: 10.1136/lupus-2020-000429

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xu, Chen, Zhang, Ma, Liu, Cui and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

AID Autoimmune disease
Erk Extracellular signal-regulated kinase
RA Rheumatoid arthritis
SLE Systemic lupus erythematosus
OXPHOS Oxidative phosphorylation
TCA Tricarboxylic acid
G6P glucose-6-phosphate
PPP Pentose phosphate pathway
NAD+ Nicotinamide adenine dinucleotide
GLUT Glucose transporter
HK Hexokinase
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
PKM2 Pyruvate kinase isoenzyme M2
PDK Phosphatidylinositol 3 kinase
Akt Serine-threonine protein kinase
mTOR Mammalian target of rapamycin
MAPK Mitogen-activated protein kinase
HIF-1α Hypoxia-inducible factor 1α
NF-κB Nuclear factor-kappa B
mTORC mTOR complexe
NETs Neutrophil extracellular traps
NAPDH Nicotinamide adenine dinucleotide phosphate
2-DG 2-deoxyglucose
ROS Reactive oxygen species
LDHA Lactic dehydrogenase A
OPA1 Optic atrophy 1
IL Interleukin
STAT Signal transducer and activator of transcription
6-biphosphatase 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
PFKFB
AMPK AMP-activated protein kinase
TLR Toll-like receptor
IC Immune complex
DC Dendritic cell
TNF-α Tumor necrosis factor-
TBK1 Tumor necrosis receptor-associated family member
associated NF-κB activator binding kinase 1
FLS Fibroblast-like synoviocyte
[18F]FDG [18F]-fluoro-2-deoxy-D-glucose
anti-CP Auto-antibodies to cyclic citrullinated peptide
PNAD Peptidyl arginine deiminase
RANKL Receptor activator of nuclear factor kappa-B ligand
ANCA Anti-neutrophil cytoplasmic antibody
AAV ANCA-associated vasculitis
MPO Myeloperoxidase
M-CSF Macrophage-colony stimulating factor 1
DMF Dimethyl fumarate
Nr2 Nuclear factor E2-related factor 2
MCT4 Monocarboxylate transporter 4
PFK-1 Phosphofructokinase-1
F2 Fructose-2,6-bisphosphate
6BP 6-bisphosphatase